"The U.S. prioritizes embryos, Japan advances induced pluripotent stem 카지노 바카라s... Korea must build a 'K-카지노 바카라 Bank' with oocyte stem 카지노 바카라s"

[by Ji, Yong Jun] The U.S. currently leads the global cell therapy market in fundamental technology through advances in embryonic stem cells (ES), while Japan has taken the lead with induced pluripotent stem cells (iPSC). Experts have cautioned that, if Korea fails to establish its own platform, it will encounter structural limitations, ultimately being forced to depend on licensing agreements and royalty payments. In this context, some have proposed the creation of a ‘Korean Cell Bank (K-Cell Bank)’ built on ovarian-derived customized stem cell technology.

Cha Kwang-ryeol, Head of the Global Research Institute at Cha Hospital and Cha Bio Group, delivered a keynote speech on September 11 at the 26th World Knowledge Forum ‘K-BIO Day & Night,’ organized by the Maeil Business Newspaper, under the theme "The Aging Human Race and the Future of 카지노 바카라 Therapy." "The United States is building its patent base in ES 카지노 바카라s, and Japan is doing so in iPSCs, but there is still no 'Korean 카지노 바카라' yet," Cha stated. "If we rely on Japanese or American products, we will inevitably have to pay licensing fees or royalties. The development of a Korean-style stem 카지노 바카라 treatment is now an urgent task."

Cha has concentrated his efforts not on ES or iPSC methods but on ‘stem 카지노 바카라 research using oocytes.’ He is internationally recognized as a leading authority in this field. In the past, the ‘slow freezing’ method developed in the United Kingdom yielded pregnancy rates of less than 1%, making clinical application impractical. However, the landscape shifted in 1988 when Cha achieved the world's first successful pregnancy using ‘frozen oocytes.’ Since then, medical institutions around the world have adopted ‘egg banking’ (also referred to as egg banks) and have applied it broadly in infertility treatment.

"If the pregnancy rate of IVF rises by just 10%, the annual number of births will increase by 16,000, leading to an overall rise in birth rates of more than 6%," Cha explained. "The use of oocyte stem 카지노 바카라s will open the door to an era of 150-year lifespans, not just 100," he predicted. "Statistical data indicate that delayed menopause extends the average lifespan by more than three years."

He also highlighted the limitations inherent in current stem 카지노 바카라 technologies, noting that because 카지노 바카라s are classified as living organisms, excessive genetic manipulation or intervention can introduce risks such as cancer development and adverse immune responses. In fact, tumor formation has been reported in overseas iPSC clinical trials. "카지노 바카라 therapies applied for anti-aging are not temporary treatments like anticancer drugs, but are often required for lifelong use, which makes ensuring their safety even more critical," Cha stated.

Cha's call for the establishment of a K-카지노 바카라 Bank was motivated not only by the need for technological independence but also by concerns over cost. Currently commercialized 카지노 바카라 and gene therapy (CGT) treatments remain prohibitively expensive, often ranging from hundreds of millions to billions of won per treatment. "If Korea continues to operate under the current system, it will be difficult for the Korean national health insurance system to sustain these costs," Cha remarked. "By developing its own platform, Korea could reduce unit costs by a factor of ten, thereby creating social value by making such treatments accessible even to developing countries."

He emphasized that building robust infrastructure is essential for Korea to position itself as a global leader in 카지노 바카라 therapy. To this end, Cha is spearheading the development of the 66,115.702m2 ‘CGB-CIC’ in Pangyo 2nd Techno Valley. The facility, created through a joint effort between CHA Bio Group and the Cambridge Innovation Center (CIC), will serve as Asia's largest bio open innovation hub.

"CGB-CIC is equipped with open laboratories and shared equipment, allowing researchers and companies to initiate 카지노 바카라 therapy research simply by joining," Cha explained. "At the CHA Bio Group level, we are capable of developing 40 카지노 바카라 therapy pipelines within two years, and with the CIC platform, that number could expand to 400-500 across Korea," he added.